Hostname: page-component-76fb5796d-22dnz Total loading time: 0 Render date: 2024-04-28T17:32:00.205Z Has data issue: false hasContentIssue false
  • English
  • Français

Korean Medication Algorithm for Bipolar Disorder 2014

Published online by Cambridge University Press:  15 April 2020

B. Yoon ,
W. Bahk ,
D. Jon ,
Y. Shin ,
J. Seo ,
J. Lee ,
Y. Woo ,
J. Jeong ,
M. Kim  and
I. Sohn
...Show all authors
B. Yoon
Affiliation:
Psychiatry, Naju National Hospital, Naju, Korea
W. Bahk
Affiliation:
Psychiatry, Yeouido St. Mary's Hospital, Seoul, Korea
D. Jon
Affiliation:
Psychiatry, Sacred Heart Hospital College of Medicine Hallym University, Anyang, Korea
Y. Shin
Affiliation:
Psychiatry, Kangbuk Samsung Hospital School of Medicine Sungkyunkwan University, Seoul, Korea
J. Seo
Affiliation:
Psychiatry, Konkuk University Chungju Hospital School of Medicine Konkuk University, Chungju, Korea
J. Lee
Affiliation:
Psychiatry, Haeundae Paik Hospital College of Medicine Inje University and Paik Institute for Clinical Research, Busan, Korea
Y. Woo
Affiliation:
Psychiatry, Yeouido St. Mary's Hospital, Seoul, Korea
J. Jeong
Affiliation:
Psychiatry, St. Vincent's Hospital, Suwon, Korea
M. Kim
Affiliation:
Psychiatry, Jeju National University Hospital, Jeju, Korea
I. Sohn
Affiliation:
Psychiatry, Keyo Hospital Keyo Medical Foundation, Uiwang, Korea
S. Shim
Affiliation:
Psychiatry, Soonchunhyang University Cheonan Hospital College of Medicine Soonchunhyang University, Cheonan, Korea
K. Min
Affiliation:
Psychiatry, Chung-Ang University Hospital College of Medicine Chung-Ang University, Seoul, Korea

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

There have been many changes in the treatment of bipolar disorder.

Objective

It is necessary to develop guidelines that can more aptly respond to cultural issues and specifics in different countries.

Aims

The Korean Medication Algorithm for Bipolar Disorder (KMAP-BP) was firstly published in 2002, with updates in 2006 and 2010. This third update reviewed the experts' consensus of opinion on the pharmacological treatments of bipolar disorder.

Methods

The newly revised questionnaire composed of 55 key questions about clinical situations including 223 sub-items was sent to the experts.

Results

Combination of mood stabilizer (MS) and atypical antipsychotic (AAP) was the first-line treatment option in acute mania. For the management of severe psychotic bipolar depression, combination of MS and AAP, combination of AAP and LTG, combination of MS, AAP and AD or LTG, combination of AAP and AD, and combination of AAP, AD and LTG was the first-line treatments. Combination of MS and AAP was the treatment of choice for management of mixed features. Combination of MS and AAP, MS or AAP monotherapy was the first-line options for management of maintenance phase after manic episode. For maintenance treatment after bipolar I depression, combination of MS and AAP, combination of MS and LTG, combination of AAP and LTG, MS or LTG monotherapy, and combination of MS, AAP and LTG were the first-line options.

Conclusion

Despite the limitations of expert consensus guideline, KMAP-BP 2014 may reflect the current patterns of clinical practice and recent researches.

Type
Article: 1160
Information
European Psychiatry , Volume 30 , Issue S1: Abstracts of the 23rd European Congress of Psychiatry , March 2015 , pp. 1
Copyright
Copyright © European Psychiatric Association 2015
Submit a response

Comments

No Comments have been published for this article.